Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
70 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2016 Summary
Global Markets Direct's, 'Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2016', provides an overview of the Opioid-Induced Constipation (OIC) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Opioid-Induced Constipation (OIC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Opioid-Induced Constipation (OIC) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC) - The report reviews pipeline therapeutics for Opioid-Induced Constipation (OIC) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Opioid-Induced Constipation (OIC) therapeutics and enlists all their major and minor projects - The report assesses Opioid-Induced Constipation (OIC) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Opioid-Induced Constipation (OIC) Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Opioid-Induced Constipation (OIC) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Opioid-Induced Constipation (OIC) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Opioid-Induced Constipation (OIC) Overview 6 Therapeutics Development 7 Pipeline Products for Opioid-Induced Constipation (OIC) - Overview 7 Opioid-Induced Constipation (OIC) - Therapeutics under Development by Companies 8 Opioid-Induced Constipation (OIC) - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Opioid-Induced Constipation (OIC) - Products under Development by Companies 11 Opioid-Induced Constipation (OIC) - Companies Involved in Therapeutics Development 12 Ironwood Pharmaceuticals, Inc. 12 Shionogi & Co., Ltd. 13 Sucampo Pharmaceuticals, Inc. 14 Synergy Pharmaceuticals, Inc. 15 Theravance Biopharma, Inc. 16 Valeant Pharmaceuticals International, Inc. 17 Opioid-Induced Constipation (OIC) - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Combination Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 (axelopran sulfate + oxycodone hydrochloride) - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 axelopran sulfate - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 dolcanatide - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 linaclotide - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 lubiprostone - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 methylnaltrexone bromide - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 methylnaltrexone bromide - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 naldemedine - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Opioid-Induced Constipation (OIC) - Recent Pipeline Updates 43 Opioid-Induced Constipation (OIC) - Dormant Projects 61 Opioid-Induced Constipation (OIC) - Discontinued Products 62 Opioid-Induced Constipation (OIC) - Product Development Milestones 63 Featured News & Press Releases 63 Nov 30, 2015: Ironwood Reports Positive Top-Line Data from Phase II Trial of Linaclotide in Adult Patients With Opioid-Induced Constipation 63 Sep 10, 2015: Theravance Biopharma Presents Positive Clinical Data on Fixed-Dose Combination (FDC) of Axelopran (TD-1211) and Oxycodone at PAINWeek 2015 63 Sep 08, 2015: Valeant And Progenics Announce FDA Acceptance Of NDA Submission For Oral RELISTOR 65 Aug 03, 2015: Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 65 Jun 24, 2015: Shionogi Announces That Naldemedine Met The Primary Endpoint In Its First Japanese Phase 3 Study For The Treatment Of Opioid - Induced Constipation In Cancer Patients 65 Jun 03, 2015: RELISTOR Receives European Approval for Expanded Indication to Treat All Opioid-Induced Constipation 66 May 19, 2015: Phase IIb Data Show Once-Daily Naldemedine Provides Significant Improvement For Patients With Opioid-Induced Constipation 66 May 15, 2015: Sucampo Announces Clinical Data on Lubiprostone to be Presented at Digestive Disease Week 67 Apr 24, 2015: RELISTOR Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain 67 Mar 30, 2015: Shionogi Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 68 Appendix 69 Methodology 69 Coverage 69 Secondary Research 69 Primary Research 69 Expert Panel Validation 69 Contact Us 69 Disclaimer 70
List of Tables
Number of Products under Development for Opioid-Induced Constipation (OIC), H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Products under Development by Companies, H1 2016 11 Opioid-Induced Constipation (OIC) - Pipeline by Ironwood Pharmaceuticals, Inc., H1 2016 12 Opioid-Induced Constipation (OIC) - Pipeline by Shionogi & Co., Ltd., H1 2016 13 Opioid-Induced Constipation (OIC) - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016 14 Opioid-Induced Constipation (OIC) - Pipeline by Synergy Pharmaceuticals, Inc., H1 2016 15 Opioid-Induced Constipation (OIC) - Pipeline by Theravance Biopharma, Inc., H1 2016 16 Opioid-Induced Constipation (OIC) - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016 17 Assessment by Monotherapy Products, H1 2016 18 Assessment by Combination Products, H1 2016 19 Number of Products by Stage and Target, H1 2016 21 Number of Products by Stage and Mechanism of Action, H1 2016 23 Number of Products by Stage and Route of Administration, H1 2016 25 Number of Products by Stage and Molecule Type, H1 2016 27 Opioid-Induced Constipation (OIC) Therapeutics - Recent Pipeline Updates, H1 2016 43 Opioid-Induced Constipation (OIC) - Dormant Projects, H1 2016 61 Opioid-Induced Constipation (OIC) - Discontinued Products, H1 2016 62
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.